Universal Beteiligungs und Servicegesellschaft mbH Raises Position in Elanco Animal Health Incorporated $ELAN

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 33.1% in the 4th quarter, HoldingsChannel reports. The firm owned 402,899 shares of the company’s stock after purchasing an additional 100,095 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Elanco Animal Health were worth $9,126,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. AlphaQuest LLC grew its position in shares of Elanco Animal Health by 13.7% during the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after buying an additional 718 shares in the last quarter. Jones Financial Companies Lllp increased its stake in shares of Elanco Animal Health by 15.2% during the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after buying an additional 798 shares during the period. US Bancorp DE raised its holdings in Elanco Animal Health by 1.9% in the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after acquiring an additional 824 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after acquiring an additional 900 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Elanco Animal Health by 43.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after acquiring an additional 938 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

ELAN has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a report on Friday, March 27th. Leerink Partners upped their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. KeyCorp increased their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Morgan Stanley raised their target price on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus target price of $27.90.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $22.76 on Monday. Elanco Animal Health Incorporated has a 12 month low of $9.26 and a 12 month high of $27.72. The firm has a market capitalization of $11.31 billion, a P/E ratio of -47.41, a P/E/G ratio of 2.90 and a beta of 1.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The company’s fifty day moving average price is $24.09 and its 200 day moving average price is $23.21.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the company posted $0.14 earnings per share. The business’s quarterly revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.03 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.